AP
FOLD

Antipodes Partners’s Amicus Therapeutics FOLD Stock Holding History

Antipodes Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,926
Closed -$55.9K – 135
2025
Q4 		$55.9K Hold
3,926
– – ﹤0.01% 105
2025
Q3 		$30.9K Buy
+3,926
New +$27.9K ﹤0.01% 107

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Antipodes Partners's FOLD Position: Q1 2026 in Review

Antipodes Partners sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 3,926 shares — an estimated $55.9K sold.

Antipodes Partners first reported a position in FOLD in Q3 2025 and held it in 2 quarters. The position peaked at $55.9K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Antipodes Partners reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Antipodes Partners sold 3,926 Amicus Therapeutics shares in Q1 2026, an estimated $55.9K.
  • Antipodes Partners first reported a position in Amicus Therapeutics in Q3 2025 and held it in 2 quarters.
  • Antipodes Partners's Amicus Therapeutics position peaked at $55.9K in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.